Patent · US Active

Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof

US11111297B2 · kind B2 · utility

0Cited by

27References

21Claims

0Family size

Assignee

Merck Sharp & Dohme LLC · US

Inventors

Michael Meehl · Lebanon, US
Philip E. Brandish · Needham, US
Laurence Fayadat-Dilman · Sunnyvale, US
Veronica Juan · Redwood City, US
Carl Mieczkowski · Mountain View, US
Latika Singh · Calle de la Era, AU

Key dates

Filing date	Nov 15, 2018
Grant date	Sep 7, 2021
Priority date	—
Expiry date	Jan 16, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.